Document is current
Any future updates will be listed below
-
Authors
Logge, Warren B. https://orcid.org/0000-0003-0777-3033
Haber, Paul S.
Hurzeler, Tristan
Gallagher, Hugh
Kranzler, Henry
Morley, Kirsten C.
-
Funding
Funding for this research was provided by:
University of Sydney
- License Information
-
More Information
Article History
Received: 5 June 2024
Accepted: 10 January 2025
First Online: 24 January 2025
Declarations
:
: Dr Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: ‘Genotype-guided dosing of opioid agonists,’ issued 26 January 2021. Dr Haber has received institutional research support from Camurus, Indivior and Woke pharmaceuticals and teaching honoraria from Camurus.
